Literature DB >> 9885295

Chemo-embolization of experimental liver metastases. Part I: distribution of biodegradable microspheres of different sizes in an animal model for the locoregional therapy.

P Bastian1, R Bartkowski, H Köhler, T Kissel.   

Abstract

An experimental in vivo rat model was established to simulate the embolization therapy of non-resectable liver metastases with microparticulate systems. The effects of biodegradable microspheres on a transplanted liver-tumor cell line in rat livers were investigated with respect to particle size. The distribution of fluorescence-labelled microspheres was investigated to characterize the effects of long-term embolization with biodegradable microspheres, and the suitability and relevance of this animal model. Novikoff hepatoma cells were implanted into the central liver lobe of Sprague-Dawley rats. After seven days, four batches of fluorescence-marked microspheres (17 microm, 25 microm, 30 microm, and 40 microm) were administered into the proper hepatic artery. Liver(including the tumor), lung and spleen were isolated and frozen sections and tissue cubes of liver-, border-, and tumor tissue were prepared. The sections were examined by fluorescence microscopy. The cubes were extracted and the fluorescence of the marker quantified. During operation, microspheres smaller than 40 microm did not cause complete embolization. The slides showed the spreading of the smaller particles to the spleen and lung. Only 40 microm particles accumulated in the liver and were rarely detectable in other organs. The extraction showed a high concentration of the 40 microm particles in the border tissue. Apparently they were trapped proximal to the tumor capillary system and therefore showed a high ratio of border/tumor concentration. Microparticles smaller than 40 microm had a border/tumor concentration ratio of less than one and were distributed to the spleen and lung. In conclusion, a mean particle diameter of at least 40 microm is required for embolization. Thus, the model shows similarity to clinical situations in the treatment of human liver tumor and metastases. Copyright 1998 Elsevier Science B.V.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9885295     DOI: 10.1016/s0939-6411(98)00047-2

Source DB:  PubMed          Journal:  Eur J Pharm Biopharm        ISSN: 0939-6411            Impact factor:   5.571


  13 in total

Review 1.  Transcatheter embolization therapy in liver cancer: an update of clinical evidences.

Authors:  Yì-Xiáng J Wáng; Thierry De Baere; Jean-Marc Idée; Sébastien Ballet
Journal:  Chin J Cancer Res       Date:  2015-04       Impact factor: 5.087

Review 2.  Rationale of transcatheter intra-arterial therapies of hepatic cancers.

Authors:  Ryan M Hickey; Robert J Lewandowski; Riad Salem
Journal:  Hepat Oncol       Date:  2014-09-09

3.  Targeted drug delivery to tumors: myths, reality and possibility.

Authors:  You Han Bae; Kinam Park
Journal:  J Control Release       Date:  2011-06-06       Impact factor: 9.776

Review 4.  Transcatheter intraarterial therapies: rationale and overview.

Authors:  Robert J Lewandowski; Jean-Francois Geschwind; Eleni Liapi; Riad Salem
Journal:  Radiology       Date:  2011-06       Impact factor: 11.105

5.  An implantable rat liver tumor model for experimental transarterial chemoembolization therapy and its imaging features.

Authors:  Xin Li; Chuan-Sheng Zheng; Gan-Sheng Feng; Chen-Kai Zhuo; Jun-Gong Zhao; Xi Liu
Journal:  World J Gastroenterol       Date:  2002-12       Impact factor: 5.742

6.  Synthesis and characterization of polystyrene embolization particles doped with tantalum oxide nanoparticles for X-ray contrast.

Authors:  Rachel Morrison; James Thompson; Luke Bird; Mark A Hill; Helen Townley
Journal:  J Mater Sci Mater Med       Date:  2015-07-30       Impact factor: 3.896

7.  Application of poly-lactide-co-glycolide-microspheres in the transarterial chemoembolization in an animal model of hepatocellular carcinoma.

Authors:  Jun Qian; Jochen Truebenbach; Florian Graepler; Philippe Pereira; Peter Huppert; Thomas Eul; Gundula Wiemann; Claus Claussen
Journal:  World J Gastroenterol       Date:  2003-01       Impact factor: 5.742

Review 8.  Transarterial therapy: an evolving treatment modality of hepatocellular carcinoma.

Authors:  Khalid A Jazieh; Mohammad Arabi; Azzam A Khankan
Journal:  Saudi J Gastroenterol       Date:  2014 Nov-Dec       Impact factor: 2.485

9.  Alginate Microspheres Containing Temperature Sensitive Liposomes (TSL) for MR-Guided Embolization and Triggered Release of Doxorubicin.

Authors:  Merel van Elk; Burcin Ozbakir; Angelique D Barten-Rijbroek; Gert Storm; Frank Nijsen; Wim E Hennink; Tina Vermonden; Roel Deckers
Journal:  PLoS One       Date:  2015-11-11       Impact factor: 3.240

10.  MRI visible drug eluting magnetic microspheres for transcatheter intra-arterial delivery to liver tumors.

Authors:  Dong-Hyun Kim; Jeane Chen; Reed A Omary; Andrew C Larson
Journal:  Theranostics       Date:  2015-02-07       Impact factor: 11.556

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.